Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Essex Investment Management Co. LLC

Essex Investment Management Co. LLC lowered its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 13.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,799 shares of the company’s stock after selling 26,717 shares during the period. Essex Investment Management Co. LLC owned approximately 0.24% of Kiniksa Pharmaceuticals worth $3,438,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter worth approximately $3,955,000. Charles Schwab Investment Management Inc. increased its position in Kiniksa Pharmaceuticals by 36.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company’s stock worth $2,414,000 after buying an additional 32,393 shares in the last quarter. Bank of New York Mellon Corp increased its position in Kiniksa Pharmaceuticals by 33.1% during the fourth quarter. Bank of New York Mellon Corp now owns 122,051 shares of the company’s stock worth $2,414,000 after buying an additional 30,382 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter worth $258,000. Finally, New York State Common Retirement Fund lifted its position in shares of Kiniksa Pharmaceuticals by 12.4% in the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock valued at $302,000 after acquiring an additional 1,680 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Performance

KNSA stock opened at $21.51 on Friday. The company has a 50 day moving average price of $19.79 and a two-hundred day moving average price of $22.33. The stock has a market capitalization of $1.55 billion, a P/E ratio of -153.63 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a one year low of $16.56 and a one year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The business had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company’s revenue was up 46.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.35 earnings per share. Research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Wedbush reiterated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and an average price target of $36.60.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the transaction, the chief operating officer now directly owns 88,975 shares in the company, valued at approximately $1,622,904. The trade was a 13.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 54.57% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.